• DOI:10.1124/dmd.105.006452
Corpus ID: 5754183

IMPACT OF CYP2C9 GENOTYPE ON PHARMACOKINETICS: ARE ALL CYCLOOXYGENASE INHIBITORS THE SAME?

@article{Rodrigues2005IMPACTOC,
  title={IMPACT OF CYP2C9 GENOTYPE ON PHARMACOKINETICS: ARE ALL CYCLOOXYGENASE INHIBITORS THE SAME?},
  author={A. D. Rodrigues},
  journal={Drug Metabolism and Disposition},
  year={2005},
  volume={33},
  pages={1567 - 1575}
}

A. D. Rodrigues

Published 2005

Medicine

Drug Metabolism and Disposition

The market withdrawals of rofecoxib (Vioxx) and valdecoxib (Bextra) have focused considerable attention on the side effect profiles of cyclooxygenase (COX) inhibitors. As a result, attempts will be made to identify risk factors in the hope that physicians might be able to ensure patient safety. At first glance, CYP2C9 genotype might be considered a risk factor because many COX inhibitors are CYP2C9 substrates in vitro. This observation has led some to hypothesize that a reduction in clearance… CONTINUE READING

View on ASPET

dmd.aspetjournals.org

Save to Library

Create Alert

Cite

Launch Research Feed